RxDoctor Payments Data

Gregory Kloehn, MD

Interventional Cardiology · Margate, FLNPI 1740269711

Payments from drug & device makers

$211,034in general payments, 2019–2025

Across 617 payments — averaging $342.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$172K
  • Penumbra, Inc.$10K
  • Medtronic$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • Abbott$5K
  • Cardiovascular Systems Inc.$3K
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$3070%
  • Speaking & faculty fees$157,53575%
  • Travel & lodging$37,64518%
  • Food & beverage$15,5287%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,034 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$170,864
Medicare patients
1,122
Services billed
2,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$105,262
Repatha SureclickEvolocumab78$50,067
JardianceEmpagliflozin66$48,628
XareltoRivaroxaban60$47,137
BrilintaTicagrelor39$22,580
EntrestoSacubitril/Valsartan15$14,784
Ezetimibe106$3,093
ClopidogrelClopidogrel Bisulfate416$2,609
Ranolazine ErRanolazine36$2,368
Isosorbide Mononitrate ErIsosorbide Mononitrate271$1,890
Metoprolol Succinate186$1,712
Atorvastatin Calcium256$1,437
Rosuvastatin Calcium52$1,140
Isosorbide Dinitrate33$968
Cilostazol95$930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$323$105,26295 claims
Boehringer IngelheimJardiance$438$48,62866 claims
Johnson & JohnsonXarelto$171,653$47,13760 claims
AstraZenecaBrilinta$95$22,58039 claims
NovartisEntresto$559$14,78415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →